Sirtris Pharmaceuticals
Investment Year
2006
Exit
2007
Sector
Geography
North America - East
Website
www.sirtrispharma.com

Sirtris Pharmaceuticals

A biopharmaceutical firm developing enzymes that activate our natural defenses against disease. Sirtris is focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, such as chronic disorders involving metabolic and inflammatory dysfunction and neurodegeneration. Its research focus is on modulating the sirtuins, a recently discovered class of enzymes involved in the aging process. Sirtris went public in May 2007 (NASDAQ:SIRT) and was acquired by GlaxoSmithKline (NYSE:GSK) in 2008.